Research Phase

 
News Articles for Research Phase top ^
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
2015/1/29
RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients; Based of FDA's feedback, RedHill and Quest Diagnostics plan to commence a study to assess the clinical utility of the diagnostic test in Q2-Q3/2015 A protocol amendment for the ongoing Phase III study of RHB-104 in Crohn's disease has been filed with FDA and is expected to significantly increase the number of patients eligible to enroll in this study The RHB-104 Phase III MAP US study for Crohn's disease is one of RedHill's three ongoing Phase III studies in the U.S. with three of its drug candidates targeting gastrointestinal diseases TEL-AVIV, Israel, Jan.
Sign-up for RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting investment picks
2015/1/22
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death Management to Host Conference Call Today at 8am PST (11am EST) LOS ANGELES , Jan.
Sign-up for CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma investment picks
2015/1/6
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients Novel Albumin-Binding Drug Candidate Appears to Allow Doxorubicin to Cross the Tumor's Blood-Brain Barrier in Humans LOS ANGELES , Jan.
Sign-up for CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer) investment picks
2014/12/22
– Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis –  SAN DIEGO, Dec.
Sign-up for Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis investment picks
2014/12/17
The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320 patients Top-line results from the Phase III GUARD study are expected during H2/2015 RedHill recently submitted a European Marketing Authorization Application (MAA) seeking approval of RHB-102 , newly branded as BEKINDA ™ , for cancer patients suffering from chemotherapy and radiotherapy-induced nausea and vomiting TEL-AVIV, Israel, Dec.
Sign-up for RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis investment picks
2015/1/8
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability 100 Percent of Patients Exhibited Decreased Skin Lesions and a Reduction in Cancer Cells LOS ANGELES , Jan.
Sign-up for CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma (KS) investment picks
2015/1/8
- Primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain - LONDON and PRINCETON, N.J., Jan.
Sign-up for GW Pharmaceuticals and Otsuka Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials investment picks
2015/2/28
Objective Response Rate Was 29% (5 of 17) in Patients With Metastatic Renal Cell Carcinoma Additional 59% (10 of 17) of Patients Achieved Stable Disease Randomized Phase 2b Study of TRC105 is Now Enrolling SAN DIEGO, Feb.
Sign-up for TRACON Pharmaceuticals Announces Positive Phase 1b Results for TRC105 in Combination With Inlyta(R) (axitinib) at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium investment picks
2014/12/8
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
2014/12/22
Trial follows successful Phase I/II study which met all study endpoints CF102 granted Orphan Drug Status for this indication by the FDA Global Industry Analysts predict that the global market for liver cancer is projected to exceed $2B by 2015 PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102 investment picks
2015/1/30
Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis Canada NewsWire MISSISSAUGA, ON , Jan.
Sign-up for Nuvo Research® Reports Topline Results of Phase 2 Study of WF10™ for the Treatment of Allergic Rhinitis investment picks
2015/2/4
REDWOOD CITY, Calif., Feb.
Sign-up for OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer investment picks
2015/1/12
SOUTH SAN FRANCISCO, Calif., Jan.
Sign-up for Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote investment picks
2014/12/1
REDWOOD CITY, Calif., Dec.
Sign-up for OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer investment picks
2014/12/7
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
2014/12/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
2014/12/9
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS , Dec.
Sign-up for Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis investment picks
2014/12/12
Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks MOUNTAIN VIEW, Calif., Dec.
Sign-up for ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 investment picks
2014/12/11
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Phase
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Permit  |  Next: Research Pipeline